Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC

Patients with resected, EGFR -mutated, stage IB to IIIA NSCLC were randomly assigned to receive adjuvant osimertinib or placebo for 3 years. The 5-year overall survival was 88% with osimertinib and 78% with placebo.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2023-07, Vol.389 (2), p.137-147
Hauptverfasser:	Tsuboi, Masahiro, Herbst, Roy S., John, Thomas, Kato, Terufumi, Majem, Margarita, Grohé, Christian, Wang, Jie, Goldman, Jonathan W., Lu, Shun, Su, Wu-Chou, de Marinis, Filippo, Shepherd, Frances A., Lee, Ki Hyeong, Le, Nhieu Thi, Dechaphunkul, Arunee, Kowalski, Dariusz, Poole, Lynne, Bolanos, Ana, Rukazenkov, Yuri, Wu, Yi-Long
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cancer therapies Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - surgery Chemotherapy Coronaviruses COVID-19 COVID-19 - etiology Critical Care Critical Care General Epidermal growth factor receptors ErbB Receptors - genetics Hematology Humans Lung Cancer Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - mortality Lung Neoplasms - surgery Mutation Neoplasm Recurrence, Local - drug therapy Non-small cell lung carcinoma Oncology Patients Placebos Pulmonary Small cell lung carcinoma Survival Analysis Targeted cancer therapy Treatments in Oncology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Patients with resected, EGFR -mutated, stage IB to IIIA NSCLC were randomly assigned to receive adjuvant osimertinib or placebo for 3 years. The 5-year overall survival was 88% with osimertinib and 78% with placebo.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2304594